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Macrophages play a paramount role in immunity and inflammation-associated diseases,
including infections, cardiovascular diseases, obesity-associated metabolic imbalances,
and cancer. Compelling evidence from studies of recent years demonstrates that
macrophages are heterogeneous and undergo heterogeneous phenotypic changes in
response to microenvironmental stimuli. The M1 killer type response and the M2 repair
type response are best known, and are two extreme examples. Among other markers,
inducible nitric oxide synthase and type-I arginase (Arg-I), the enzymes that are involved
in L-arginine/nitric oxide (NO) metabolism, are associated with the M1 and M2 pheno-
type, respectively, and therefore widely used as the markers for characterization of the
two macrophage phenotypes. There is also a type-II arginase (Arg-II), which is expressed
in macrophages and prevalently viewed as having the same function as Arg-I in the cells.
In contrast to Arg-I, little information on the role of Arg-II in macrophage inflammatory
responses is available. Emerging evidence, however, suggests that differential roles of Arg-I
and Arg-II in regulating macrophage functions. In this article, we will review recent devel-
opments on the functional roles of the two arginase isoforms in regulation of macrophage
inflammatory responses by focusing on their impact on the pathogenesis of cardiovascular
diseases and metabolic disorders.
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INTRODUCTION
Macrophages are important sentinel cells in our body and
are involved in maintenance of tissue homeostasis, immune
responses, and inflammation-associated diseases. Recent findings
have revised our traditional view on the origin and biological func-
tions of macrophages. We now know that tissue macrophages are
not only recruited from bone marrow-derived monocytes but also
differentiated from yolk sac-derived embryonic stem cells (1–3).
Moreover, tissue macrophages are not terminally differentiated
and are maintained throughout life by local proliferative self-
renewal (4,5). Importantly,macrophages are highly heterogeneous
and undergo phenotypic changes, i.e., macrophage plasticity, in
response to specific signals as a consequence of adaptation to
local tissue environmental cues (6, 7). The original and the best
known types of macrophage responses are the pro-inflammatory
M1 type (killer cells) and the anti-inflammatory M2 type (repair
type cells) (3, 7). There are convincing evidences from research
of recent years showing that different phenotypic macrophages
are indeed importantly participating in the process of immune
and inflammatory responses, which have been reviewed by many
comprehensive articles (7, 8).
MACROPHAGE POLARIZATION
Macrophage polarization describes acquirement of distinctive
phenotypic and functional characteristics of fully differentiated
macrophages in response to microenvironmental stimuli.
Functional polarization of macrophages and the underlying
mechanisms that control the cell phenotypes are complex and
have been extensively investigated in recent years. As mentioned,
the M1 and M2 classifications of macrophages described the two
major and opposing activities committed to killing and repairing
functions of the cells. It is emerging that macrophage polar-
ization is regulated by a broad spectrum of recognition recep-
tors, cytokines, specific signaling pathways, and genetic programs.
Some of them are used as markers or functional repertoire of the
macrophage phenotypes. There are, however, no standard guide-
lines for classification of macrophage phenotypes. Most impor-
tantly, information about functions of these markers in regulation
of macrophage inflammatory responses or phenotypes is either
lacking or controversial. The conclusions are usually based on
association studies. It is generally the view that M1 macrophages
express enhanced genes, which are pro-inflammatory and cyto-
toxic, typically inducible nitric oxide synthase (iNOS)/NO, IL-12,
class II MHC, and the chemokines IL-8 and CCL2, participat-
ing in killing intracellular parasites and tumor development.
In contrast, M2 macrophages produce more anti-inflammatory
cytokines and substances involved in repairing function, typi-
cally, arginase/ornithine, EGF, VEGF, and TGF-β, and mannose
receptor (9). This phenotypic cell is mainly participating in reso-
lution of inflammation, tissue repairing, angiogenesis, allergy, and
tumor progression (10). It is, however, to notice that M1 and M2
activation programs display differences, but they may not form
clear-cut activation subsets and reveal overlapping effects. A dis-
cussion about the complexity of macrophage phenotype markers,
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differentiation mechanisms, and the roles in human diseases is
beyond the scope of this review article. For these aspects, readers
are kindly asked to refer to several comprehensive review articles
(11, 12). In the following section of this article, we will focus on dis-
cussing the role of the enzymes arginase and nitric oxide synthase
(NOS) that are involved in l-arginine metabolism in various cell
types including vascular endothelial cells and macrophages and
widely used as markers to distinguish M1 and M2 macrophage
phenotypes.
L-ARGININE METABOLISM, iNOS, AND ARGINASE IN
MACROPHAGE FUNCTIONAL POLARIZATION
The suggestion that l-arginine metabolism could be involved in
regulation of macrophage phenotypes was from early studies with
macrophages isolated from the Th1 strain mouse C57B1/6 and
Th2 strain BALB/c mouse (13, 14). These studies demonstrate that
isolated macrophages from Th1 strain C57Bl/6 mouse are more
readily activated to produce nitric oxide (NO) upon stimulation
with IFN-γ or lipopolysaccharide (LPS) than the macrophages
from Th2 strain BALB/c mouse. Later on, it was characterized
that M1 macrophages are more easily activated by LPS to produce
cytotoxic NO via iNOS, whereas M2 macrophages generate lit-
tle NO but more ornithine from the same substrate l-arginine via
arginase (15). The iNOS and arginase are thought to affect inflam-
matory responses in the opposite way. NO production from iNOS
in M1 macrophages inhibits cell proliferation and kills pathogens,
a M1 killing type response (16, 17), while ornithine production
promotes cell proliferation and repairs tissue damage through
generation of polyamines and collagen in M2 macrophages, a M2
repairing type response (11, 18). Both NO and ornithine are gen-
erated from the same substrate l-arginine via iNOS and arginase,
respectively (11, 18) (Figure 1). From these studies, one can con-
sider dominant NO production as M1 activity, whereas dominant
ornithine production as M2 activity of macrophages.
ARGINASE ISOENZYMES AND L-ARGININE METABOLIZING
FUNCTIONS
In human beings and mammals, there are two isoforms of arginases,
arginase-1 (Arg-I) and arginase-II (Arg-II). Both isoenzymes are
FIGURE 1 | L-arginine metabolism by iNOS and arginase and the
functional consequences in macrophages. ODC, ornithine
decarboxylase; OAT, ornithine aminotransferase.
encoded by two separate genes. In human beings, Arg-I gene
maps to chromosome 6q23 and encodes a 322 amino acid pro-
tein (19–21), while Arg-II gene maps to chromosome 14q24.1
and encodes a 354 amino acid protein (22–24). At the subcel-
lular level, Arg-I is mainly localized in cytoplasm and Arg-II in
mitochondrion (25). The physiological role of the different sub-
cellular compartmentation of the two isoenzymes is not known.
The two isoenzymes, however, share similar structure, reveal more
than 50% of homology of their amino acid residues with 100%
homology in the areas, which are critical for their l-arginine
metabolizing function (22, 23, 26). Although both Arg-I and Arg-
II are to hydrolyze l-arginine to produce urea and l-ornithine
(25), the functional impact of the two isoenzymes is either sim-
ilar or different depending on specific organs/cells. For example,
increased activity and/or expression of either Arg-I or Arg-II in
endothelial cells impair the vasoprotective endothelial NO produc-
tion via eNOS (27). However, in macrophages, Arg-I and Arg-II
seem to play an opposite function, which we will discuss later in
this article. The primary function of Arg-I is to remove exces-
sive nitrogen produced from amino acid metabolism through
hepatic urea cycle, which is otherwise toxic for our body (28,
29), because Arg-I is constitutively and abundantly expressed as
a cytosolic enzyme in the liver (30). No Arg-II could be detected
in hepatocytes. The vital effect of hepatic Arg-I is evidenced by the
studies showing that Arg-I knockout mice reveal severe symp-
toms of hyperammonemia and die between postnatal days 10
and 14 (31). Patients with Arg-I deficiency due to gene mutation
reveal urea cycle disorder, hyperargininemia, and exhibit progres-
sive neurologic impairment, development retardation, and hepatic
dysfunction associated with cirrhosis and carcinoma in early child-
hood (28, 29). Arg-I has been reported to be expressed also in
many extrahepatic tissues such as stomach, pancreas, and lung
(32). The functions of Arg-I in these organs are far from clear.
Unlike Arg-I, Arg-II is confined mainly to kidney, brain, prostate,
intestine, and also pancreas (22, 23, 32). The functions of Arg-
II in these organs are not known. The best characterization of
Arg-II function is done in vascular endothelial cells in which the
isoenzyme, similar to Arg-I, metabolizes l-arginine to urea and l-
ornithine, which limits l-arginine bioavailability for generation of
the vasoprotective NO via eNOS, resulting in vascular endothelial
dysfunction (33, 34). This effect of arginases on endothelial cells is
attributable to eNOS-uncoupling, a situation that eNOS enzyme
produces increased superoxide anion, but decreased NO (34–39),
which is thought to be attributed to l-arginine deficiency, leading
to oxidative stress, and enhanced expression of endothelial inflam-
matory adhesion molecules such as VCAM-1 and ICAM-1 (39),
since endothelial NO reveals important anti-oxidative and anti-
inflammatory functions and suppresses expression of the adhesion
molecules (40). These effects of Arg-II are dependent on the enzy-
matic activity, since loss-of-function point mutation of histidine
to phenylalanine at position 160 in Arg-II abolishes its l-arginine–
urea hydrolase activity and is unable to cause eNOS-uncoupling
and the inflammatory responses in endothelial cells (39). We have
recently reviewed the aspect of arginase in eNOS-uncoupling (41).
Arginase also exerts pleiotropic effects, i.e.,l-arginine–urea hydro-
lase activity-independent effect, which we will discuss later in this
article.
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ARGINASE ISOENZYMES AND MACROPHAGE FUNCTIONS
As mentioned above, macrophages are heterogeneous and undergo
phenotypic changes, depending on microenvironmental stimuli.
The expression of Arg-I and Arg-II is inducible in macrophages
depending on external stimuli (42, 43). As discussed, NO from
iNOS in macrophages is linked to M1, whereas ornithine generated
from arginase is associated with M2 phenotype (11). Substan-
tial number of studies demonstrates that Arg-I is dominantly
expressed in M2 cells and reduces NO production from iNOS
through limiting bioavailability of intracellular l-arginine, result-
ing in dampening of inflammatory tissue damage and suppression
of clearance of intracellular pathogens (44–48). In contrast to Arg-
I, only very little and even contradictory information is available
about the expression and role of Arg-II in macrophage phenotype
regulation and inflammatory responses. Until we have systemati-
cally investigated this specific aspect in macrophage inflammatory
responses (43), the function of Arg-II in macrophages is believed
to be anti-inflammatory, which is extrapolated from its similar
function as Arg-I on l-arginine/NO metabolism. An early study
showed that Arg-II gene is a direct target of liver X receptor that
has been shown to exert inhibitory effects on expression of inflam-
matory genes in macrophages (49). Based on this association, the
authors suggest that Arg-II is anti-inflammatory. The functional
analysis is, however, not done. It is of particular importance to note
that LPS stimulation exclusively enhances iNOS in macrophages
associated with M1 phenotype (43, 50). We could demonstrate
that iNOS induction in macrophages is paralleled with enhanced
expression of Arg-II, but not Arg-I (43), which suggests that
Arg-I and Arg-II shall have different functions in macrophage
inflammatory responses or phenotype regulation. In line with this
observation, accumulation of Arg-II-expressing macrophages is
associated with advanced atherosclerotic lesions in which pro-
inflammatory cells are dominant (42), suggesting that Arg-II is
associated with pro-inflammatory responses. Because of this con-
tradictory concept about the role of Arg-II and lack of functional
analysis of Arg-II in macrophage inflammatory responses, we
recently systematically characterized the role of Arg-II in regula-
tion of macrophage inflammations at the cellular and whole body
levels in mouse models of chronic inflammatory diseases such
as obesity-linked insulin resistance, type-II diabetes mellitus, and
atherosclerosis (43).
In this study, we demonstrate that M1 activation of
macrophages by LPS exclusively up-regulates iNOS and Arg-II,
but not Arg-I expression in murine and human macrophages
(43). Silencing Arg-II gene in human monocyte/macrophage cell
lines decreases the cell adhesion to endothelial cells with reduced
production of pro-inflammatory cytokines in response to LPS or
ox-LDL at both the mRNA and protein levels. Moreover, LPS-
induced up-regulation of numerous pro-inflammatory media-
tors, including MCP-1, TNF-α, IL-6, MMP14, and iNOS, is sig-
nificantly suppressed in macrophages isolated from Arg-II−/−
mice as compared with those from wild-type control animals.
Convincingly, introducing Arg-II gene back to the Arg-II−/−
macrophages restores or enhances the LPS-stimulated expression
of the pro-inflammatory genes to much higher levels compared to
the Arg-II+/+ cells from wild-type mice. Importantly, Arg-II−/−
mice are protected from systemic pro-inflammatory macrophage
infiltration in various organs and expression of pro-inflammatory
mediators in high-fat diet (HFD)-induced obesity. Arg-II−/−mice,
when fed a HFD, although have similar body weight as WT con-
trols, reveal lower fasting plasma glucose concentration, are more
glucose tolerant and insulin sensitive (43) as compared to WT
mice on HFD. Interestingly, Arg-II levels in macrophages are sig-
nificantly increased in WT mice fed HFD, which is associated
with pro-inflammatory responses. The pro-inflammatory func-
tion of Arg-II in macrophages is further demonstrated in another
chronic inflammatory disease model, i.e., atherosclerosis mouse
model (43). Knocking-out Arg-II gene in the atherosclerosis-
prone ApoE−/− mice (ApoE−/−/Arg-II−/−) decreases inflam-
matory cytokine levels and macrophage content in the aortas,
reduces atherosclerotic plaque formation, and reveals more sta-
ble plaque features as compared to ApoE−/−Arg-II+/+ control
mice. Since M1 pro-inflammatory macrophages play crucial role
in development of insulin resistance and type-II diabetes and
atherogenesis (51–55), our results demonstrate that Arg-II pro-
motes pro-inflammatory or M1 phenotype of macrophages and
favors chronic inflammatory disease development such as obesity-
associated insulin resistance, type-II diabetes, and atherosclerosis.
It is to mention that the pro-inflammatory effect of Arg-II in
macrophages does not seem to be relying on iNOS, since inhibition
of iNOS does not significantly affect expression of several pro-
inflammatory genes in macrophages. The dissociation of arginase
activity from iNOS has been reported by several studies, showing
that alteration of arginase activity in macrophages is not neces-
sarily associated with functional changes in iNOS (56–59). These
iNOS-independent pro-inflammatory responses mediated by Arg-
II in macrophages are due to enhanced mitochondrial ROS, since
reintroduction of the Arg-II gene into Arg-II−/− macrophages
enhances mitochondrial O−2 and H2O2 generation and inhibi-
tion of mitochondrial ROS significantly reduces Arg-II-mediated
inflammatory responses. The function of Arg-II in comparison
with Arg-I in macrophage inflammatory responses and chronic
inflammatory diseases, i.e., atherosclerosis and insulin resistance
is summarized in Figure 2. It is not very surprising, since Arg-II is
a mitochondrial enzyme (60). The question remains elusive how
Arg-II affects mitochondrial function leading to mitochondrial
ROS production in macrophages.
Although we have characterized the function of Arg-II in
macrophages, many important questions remain unanswered. In
the following section, we will briefly discuss several important
remaining questions regarding the role of arginase isoenzymes in
macrophage functions.
FUTURE RESEARCH QUESTIONS AND PERSPECTIVES
DOES Arg-I PLAY A CAUSAL ROLE IN M2 MACROPHAGE PHENOTYPE?
As discussed, Arg-I is constitutively expressed in hepatocytes and
is inducible in macrophages, e.g., by Th2 cytokines IL-4 and
IL-13 (44, 61, 62). It is highly upregulated in M2 macrophages
and widely used as a M2 macrophage marker (11). It has been
suggested that Arg-I in macrophages promotes Th2 cytokine pro-
duction, contributing to resolution of inflammation and tissue
repairing (63). A study in human smooth muscle cells showing
that overexpression of Arg-I gene is able to decrease LPS-induced
pro-inflammatory cytokine production (64), seems to support the
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FIGURE 2 |The distinct role of Arg-I and Arg-II in macrophage
inflammatory responses. Dashed line indicates that the causal role of
Arg-I in M2 phenotype requires determination.
anti-inflammatory function of Arg-I. However, mice with spe-
cific Arg-I gene deficiency in macrophages show exacerbated Th2
response and fibrosis in the liver of Schistosoma mansoni infected
mice (65), which does not seem to support previous suggestions
in promotion of Th2 responses (63). Most studies demonstrate
only the positive correlation of Arg-I with M2 macrophage pheno-
type, the causal relationship of Arg-I with macrophage phenotype
is, however, not fully clear. Importantly, a recent study demon-
strates that Arg-I deficient mouse macrophages has even higher
polyamine production and does not impair gene expression in
response to IL-4 (66), which raises the question about the role
of Arg-I in M2 macrophage regulation. Future research shall
elucidate the causal role of Arg-I in regulation of macrophage
functional polarization.
DOES L-ARGININE DEFICIENCY EXPLAIN THE FUNCTIONS OF ARGINASE
ISOENZYMES IN MACROPHAGES?
There is continuing debate about the role of l-arginine defi-
ciency in arginase-induced alterations of cellular functions. It
is generally believed that arginase including Arg-I and Arg-II
causes l-arginine deficiency, resulting in decreased NO produc-
tion from eNOS in endothelial cells (endothelial dysfunction) and
from iNOS in macrophages (M2 type function) (41). It has been
demonstrated that the concentration of l-arginine in adult human
and mouse plasma (0.1 mmol/L), as well as intracellular arginine
concentration (0.05–0.2 mmol/L) far exceed the Km of eNOS (2–
20µmol/L) (67). Even though, acute l-arginine supplementation
in cells, isolated blood vessels, or in animals or in patients is able
to enhance NO production and improve endothelium-dependent
relaxations, a situation called “arginine paradox” (68, 69). This
phenomenon led to doubt whether l-arginine deficiency caused by
arginase is true. Several hypotheses have been proposed to explain
the “arginine paradox.” First, a “relative” intracellular l-arginine
deficiency, resulting from an increased level of endogenous com-
petitors for eNOS substrate l-arginine such as ADMA that binds
to eNOS but could not be metabolized by the enzyme on top of
increased arginase activity either Arg-I or Arg-II in endothelial
cells has been suggested (70). Experiments showed that inhibition
of arginase improves eNOS function and overexpression of Arg-I
or Arg-II causes eNOS-uncoupling, leading to oxidative stress, and
decreased bioavailability of endothelial NO production, which is
associated with only 11–25% reduction in intracellular l-arginine
concentration in the presence of high-extracellular concentration
of l-arginine (0.4 mmol/L) (71). These results seem to support the
“relative l-arginine deficiency” hypothesis. It is worthy of noting
that NO production, particularly, iNOS/NO can be inhibited by
TGF-β, which is a strong Arg-I up-regulator and present in very
high amount during wound healing (72). It is presumable that NO
production is inhibited even under the condition of high-plasma
l-arginine concentration because of high concentration of TGF-β.
Whether this could explain the “arginine paradox” is not known.
Another alternative hypothesis is that a specific intracellular pool
of l-arginine for NO production may exist in endothelial cells
and could be depleted by enhanced arginase (73), yet, it is highly
speculative. It is not known whether enhanced arginase activity,
particularly Arg-II, could also cause iNOS-uncoupling, affecting
macrophage functions. Another puzzling is that why Arg-I and
Arg-II share the same l-arginine metabolizing function but seem
to exert distinct effects on macrophages.
If there is no real l-arginine deficiency caused by arginase either
Arg-I or Arg-II, l-arginine supplementation therapy aiming to
enhance endothelial NO production and to treat vascular disease
shall not work. In accordance, clinical studies in patients with acute
myocardial infarction or with peripheral arterial disease demon-
strate that 6-month oral l-arginine supplementation (3 g three
times a day on top of standard medications) increase mortality
and shorten walking distance accompanied with decreased NO
production as compared to the placebo group (74). The underlying
mechanisms are not known and may be related to the induc-
tion of arginase, particularly Arg-II in vascular endothelial cells
by chronic l-arginine exposure as demonstrated by recent stud-
ies including our own (37, 69). These studies show that acute
supplementation of l-arginine to endothelial cells increases NO
bioavailability, while chronic l-arginine supplementation causes
eNOS-uncoupling mediated by up-regulation of Arg-II levels,
leading to endothelial senescence (69). Similar to this finding,
l-arginine has also been reported to cause iNOS-uncoupling in
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macrophages (75). These studies do not support a role of absolute
l-arginine deficiency caused by arginase, but strongly implicate
that too much l-arginine is even harmful, which is probably due
to production of other undesired metabolites from l-arginine as
speculated (76). Alternatively, a pleiotropic effect may also provide
explanation for the detrimental effects of arginase at least for Arg-
II under the condition of sufficient l-arginine supply. This point
will be discussed below.
DOES ARGINASE EXERT PLEIOTROPIC EFFECTS: L-ARGININE–UREA
HYDROLASE ACTIVITY-INDEPENDENT EFFECTS?
Any proteins or enzymes may have pleiotropic or off-target effects
that are not necessarily related to their canonical functions. We
have recently discovered that Arg-II exhibits its biological func-
tions in vascular cells through both mechanisms, which are either
dependent or independent on l-arginine metabolizing function
(l-arginine–urea hydrolase activity) (77). We show that the cat-
alytically inactive mouse Arg-II mutant with a point mutation of
histidine to phenylalanine at position 160 (referred to as H160F),
which lost its l-arginine–urea hydrolase activity, although does
not cause eNOS-dysfunction in endothelial cells, promotes cell
apoptosis and senescence to the same extent as the WT Arg-II
in vascular smooth muscle cells (VSMC). In contrast, only the
WT Arg-II (not the H160F inactive mutant) exerts function to
promote VSMC proliferation (Figure 3), which can be attributed
to the production of polyamine from l-arginine/ornithine path-
way. This intriguing result provides evidence that Arg-II on one
hand promotes VSMC proliferation and on the other hand causes
VSMC apoptosis and senescence. While the cell proliferation–
stimulating effect of Arg-II is dependent on its l-arginine–urea
hydrolase activity via synthesis of ornithine and polyamines (71,
78), the cell apoptosis/senescence-promoting effect is independent
of its enzymatic activity (Figure 3). Further experiments show that
this l-arginine–urea hydrolase activity-independent effect is medi-
ated through signaling pathways including mTORC1/S6K1, JNK,
and ERK1/2, converging on p66Shc leading to H2O2 production
and mitochondrial dysfunction leading to cellular apoptosis and
senescence (77) (Figure 3). In parallel to these signaling pathways,
p53 is also activated by Arg-II independently of its l-arginine–
urea hydrolase activity, contributing to the cell senescence of the
FIGURE 3 | Canonical and pleiotropic effects of Arg-II in vascular endothelial and smooth muscle cells and underlying signaling mechanisms in
development of vascular aging and age-associated vascular diseases.
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apoptosis process. Importantly, expression of Arg-II and activities
of S6K1, ERK1/2, p66Shc, and p53 are all augmented in senes-
cent VSMC, and genetic inhibition or ablation of Arg-II not only
reduces these signaling pathways and VSMC senescence/apoptosis
in vitro but also in atherosclerosis-prone ApoE−/− mice in vivo,
which at least in part accounts for the reduced plaque lesion for-
mation and a more stable plaque characteristics in aortic roots in
Arg-II-deficient ApoE−/− mice (43, 77) (Figure 3). Moreover, we
also show that Arg-II negatively regulates autophagy function –
a cell protective mechanism of lysosomal proteolysis aiming to
remove harmful proteins (79) – in endothelial cells, which is also
independent on its l-arginine–urea hydrolase activity [Ref. (69),
Figure 3]. Decreased autophagy function in vascular cells and
macrophages are implicated in vascular aging and atherosclerotic
vascular disease. Indeed, recent studies provide evidence suggest-
ing that adequate induction of autophagy protects against cellular
injury in endothelial and smooth muscle cells and formation of
foam cells, resulting in anti-atherosclerotic effects (80–82). In line
with this finding, genetic ablation of Arg-II in atherosclerotic
ApoE−/− mice preserves endothelial autophagy in aortas, which
associates with reduced atherosclerosis lesion formation (69). In
this study, we also demonstrate that Arg-II impairs endothelial
autophagy independently of the l-arginine–urea hydrolase activ-
ity through activation of mTORC1/S6K1 and p53, resulting in
inhibition of AMPK in endothelial cells, which contributes to
development of atherosclerosis (Figure 3). How Arg-II, indepen-
dently of its l-arginine–urea hydrolase activity, impacts vascular
cell functions, remains to be investigated. Further, whether these
enzymatic dependent and independent effects also exist for Arg-
I and whether the pleiotropic effects of arginase account for
functional regulations in macrophages are unknown.
WHAT ARE THE MECHANISMS THAT REGULATE Arg-I AND Arg-II IN
MACROPHAGES
Arginase-I gene expression is inducible in macrophages by a vari-
ety of stimuli, for example, by elevated cAMP, IL-4, and TGF-β
(50). The regulation of Arg-I gene expression is mainly investi-
gated at the transcriptional levels in murine macrophages, while
it remains to be investigated whether the findings are also true
in human cells. A number of transcription factors and nuclear
receptors such as RXR, PPARγ, PPAR δ, STAT6, C/EBPβ, KLF4,
PU.1, IRF8, and AP-1 have been shown to bind directly to spe-
cific sites in the promotor region of Arg-1 gene and in turn to
enhance Arg-1 expression. The complexity of Arg-I gene regula-
tion mechanisms are further complicated by the fact that these
transcription factors can be regulated by post-translational mod-
ification mechanisms such as SUMOylation and ubiquitination
that are participating in the regulation of Arg-1 gene [for detailed
description of these mechanisms please refer to the review articles
(83, 84)]. There is, however, little information available regarding
the upstream regulatory mechanisms involved in gene expression
and enzymatic activity of Arg-I in macrophages. Also, very limited
information is provided on regulation of Arg-II in macrophages.
The stress sensor p38mapk has been demonstrated to partici-
pate in up-regulation of activity and expression of Arg-I and
Arg-II in macrophages (85, 86). This seems to be also the case
in bovine and rat aortic endothelial cells for Arg-I expression
(87) and in human endothelial cells and mouse penile tissues
for Arg-II (88, 89). In accordance, in vivo treatment of hyperten-
sive mouse induced by angiotensin-II infusion with a p38mapk
inhibitor prevents elevation of Arg-II expression and activity and
enhances endothelium-dependent relaxation (88). These studies
demonstrate that p38mapk is the upstream regulator of Arg-
II in endothelial cells and macrophages. Our most recent study
provides evidence showing that p38mapk also functions as down-
stream effector of Arg-II in endothelial cells, causing oxidative
stress through eNOS-uncoupling, since overexpression of Arg-II in
human endothelial cells causes eNOS-uncoupling and augments
p38mapk activation (90), and inhibition of p38mapk either phar-
macologically by SB203580 or genetically by silencing the major
isoform p38mapkα in endothelial cells prevents eNOS-uncoupling
effect by Arg-II gene overexpression (90). Furthermore, mice fed
HFD, an obesity mouse model, exhibit enhanced Arg-II expres-
sion/activity and p38mapk activity and eNOS-uncoupling in the
aortas and inhibition of p38mapk recouples eNOS activity in the
obese mice. Moreover, mice deficient in Arg-II (Arg-II−/−) on
the same obesogenic diet reveal decreased p38mapk activity and
eNOS function is fully preserved. These results demonstrate that
Arg-II causes eNOS-uncoupling through activation of p38mapk
in HFD-induced obesity (90). Together with the experiments dis-
cussed above, there might be a positive regulatory circuit between
p38mapk and Arg-II at least in vascular endothelial cells. Whether
this mechanism is also involved in Arg-I and/or Arg-II gene expres-
sion in macrophages is not known. A similar positive regulatory
circuit between S6K1 and Arg-II has also been demonstrated by
our recent studies in vascular endothelial cells (39).
In this study, we show that a persistent hyperactive S6K1 activity
is found to play a causal role in eNOS-uncoupling, leading to vas-
cular endothelial aging and senescence (39, 91). Overexpression
of a constitutively active S6K1 mutant up-regulates Arg-II (not
Arg-I) gene expression and arginase activity in non-senescent cells
by stabilizing Arg-II mRNA (39). Conversely, silencing S6K1 in
senescent cells reduces Arg-II gene expression and activity and
genetic or pharmacological inhibition of S6K1 in senescent cells
or in old rat aortas decreases Arg-II gene expression and activity,
demonstrating a critical role of hyperactive S6K1 in up-regulating
Arg-II gene expression, resulting in enhanced arginase activity in
endothelial aging. Interestingly, silencing Arg-II gene in senes-
cent endothelial cells or deficiency in Arg-II gene in mice reduces
S6K1 activity, recouples eNOS function in aging, and inhibits
endothelial expression of adhesion molecules such as ICAM-1
and VCAM-1, resulting in inhibition of monocyte-endothelial
cell interaction, demonstrating a positive vicious cycle between
S6K1 and Arg-II in vascular endothelial aging. These studies pro-
vide evidence showing that a mutual positive regulation between
S6K1 and Arg-II gene expression accelerates endothelial aging
through eNOS-uncoupling, leading to oxidative stress and inflam-
mation (39). Further studies will analyze whether S6K1 is also
involved in regulation of Arg-I and/or Arg-II in macrophages,
participating in macrophages phenotype determination. Also, the
relationship between p38mapk, S6K1, and arginase remain to be
analyzed.
Other signaling pathways such as GTPase RhoA and its down-
stream kinase ROCK have been reported to mediate Arg-I gene
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expression in porcine coronary arterioles in response to hydro-
gen peroxide (H2O2) and peroxynitrite (92) and Arg-II (but not
Arg-I) expression and/or activity in women with preeclampsia
(93) and in human endothelial cells in response to thrombin
(35), oxidized LDL (94), and hyperglycemia (36). In macrophages,
however, ROCK kinase inhibitor enhances Arg-I expression and
shift M1 to M2 phenotype (95), suggesting that ROCK pathway
may inhibit Arg-I expression. No information is available so far
whether Rho/ROCK pathway is involved in Arg-II regulation in
macrophages. For the detailed regulatory signaling mechanisms
of Arg-I and Arg-II expression/activity in vascular cells, please
refer to the review article (41).
CONCLUSION
The two isoforms of arginase, i.e., Arg-I and Arg-II, although
located in different subcellular compartments, share the same
function on l-arginine metabolism. Both isoenzymes hydrolyze
l-arginine to urea and l-ornithine, resulting in eNOS-uncoupling
in endothelial cells. In macrophages,Arg-I and Arg-II can be differ-
entially induced by external stimuli. Evidence has been provided
that Arg-II plays a causal role in M1 functions, whereas Arg-I
is associated with M2 function in macrophages and widely used
as M2 marker for macrophages. However, the causal relationship
between Arg-I and M2 phenotype warrants further investiga-
tion. It remains to be characterized how Arg-I and Arg-II share
the same l-arginine metabolizing effect, but exhibit distinct or
opposite effects in macrophage inflammatory responses. Arg-II
as therapeutic target in chronic inflammatory disorders such as
age-associated vascular dysfunctions, atherosclerosis, and type-II
diabetes and complications has shown promising beneficial effects
in genetic modified mouse models (39, 43, 96). Some studies
implicate that targeting Arg-I is also beneficial for cardiovascular
functions, these studies are solely dependent on the pharmacolog-
ical inhibitors, which inhibit both isoforms of arginases (97–99),
since systemic Arg-I deficient mouse exhibits severe symptoms
of hyperammonemia, and die between postnatal days 10 and 14
(31), one should consider that these inhibitors could inhibit liver
Arg-I, resulting in hyperammonemia. Taking into account that
Arg-I in macrophages may exhibit opposite effects as Arg-II, this
is another important reason to develop specific Arg-II inhibitors.
Moreover, whether Arg-I and Arg-II exert pleiotropic effects on
macrophage functions as demonstrated in vascular cells shall be
investigated. If this proves to be true, development of therapeu-
tic drugs that target l-arginine–urea hydrolase activity may have
limitation on treatment of inflammatory diseases. Additionally,
signaling pathways that are involved in regulation of gene expres-
sion and enzymatic activity of both Arg-I and Arg-II shall be
further elucidated in macrophages. Characterization of these sig-
naling mechanisms will also provide possibilities or rationales to
target arginase isoforms specifically in an indirect way to treat
inflammatory diseases. Finally, we have focused on cardiovascular
and metabolic diseases here. But, functional analysis of arginase
isoenzymes and their roles in macrophage polarization should
also help understanding other diseases, notably cancer. In partic-
ular, monocytes and macrophages are recruited into tumors and
regulate tumor growth by changing their functional phenotypes,
which is originally demonstrated by Mills and colleagues (100).
M1 macrophage has been shown to have antitumor immunity,
whereas the M2 macrophage exerts protumorigenic properties
(101). Regardless of the inflammatory circumstance, it appears
that macrophage arginases are key players in influencing disease
outcomes.
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